Expression of B Cell Translocation Gene 1 Protein in Colon Carcinoma and its Clinical Significance

2020 ◽  
Vol 15 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Junhe Zhang ◽  
Weihua Dong
Keyword(s):  
Colon Cancer ◽  
Survival Rate ◽  
B Cell ◽  
Lymphatic Metastasis ◽  
Clinicopathological Features ◽  
Cumulative Survival Rate ◽  
Control Group ◽  
Observation Group ◽  
Cox Regression Analysis ◽  
Cumulative Survival

Background: Colon cancer is one of the most common malignant tumors, and B cell Translocation Gene (BTG)1 is involved in the occurrence and development of colon cancer, however, the underlying molecular mechanism remains unclear. Objective: In this study, we investigated the expression of BTG1 protein in colon cancer, and its association with clinicopathology and prognosis. Methods: The tumor specimens from 59 patients with colon cancer who had undergone radical colectomy were selected as the observation group. Para-carcinoma tissues from the same patients were selected as the control group. The expressions of BTG1 mRNA and protein in the specimen of two groups were analyzed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot. According to the immunohistochemical results, the patients were divided into BTG1-negative and BTG1-positive groups. The postoperative cumulative survival rate in the two groups was analyzed. The association of the expression of BTG1 protein with the clinicopathological features and postoperative survival was investigated. Results: Compared with the control group, the expression levels of BTG1 mRNA and BTG1 protein were significantly decreased in the observation group (P < 0.05). Immunohistochemical analysis revealed that there were 12 positive tumor samples and 47 negative samples. The expression of BTG1 was negatively associated with the degree of differentiation and lymphatic metastasis. The cumulative survival rate of BTG1-positive patients was significantly increased compared with that of BTG1- negative patients (P < 0.05). Stepwise Cox regression analysis showed that lymphatic metastasis, tumor size and BTG1 expression level were independent prognostic factors for overall survival in patients with colon cancer. Conclusion: BTG1 protein in colon cancer tissues were expressed at low levels, which was associated with the clinicopathological features, postoperative recurrence and survival of patients.

scholarly journals Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Haiyang Zhao ◽  
Zhiqiang Ren ◽  
Guangwen Wang
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Survival Rate ◽  
Cumulative Survival Rate ◽  
Control Group ◽  
Observation Group ◽  
Cumulative Survival ◽  
The Difference ◽  
Tcm Syndrome

Objective. To observe the clinical effects of Jiawei Danggui Beimu Kushen pills in treating prostate cancer and their influence on the expression of serum prostate specific antigen. Methods. A total of 234 prostate cancer patients were selected and randomly divided into observation group and control group, with 117 cases in each group. The control group was given oral bicalutamide tablets, while the observation group was treated with Jiawei Danggui Beimu Kushen pills on the basis of the control group. The treatment efficacy, IPSS score, TCM syndrome score, VAS score, quality-of-life score, and immune function of the two groups were compared before and after treatment. The serum PSA and f-PSA levels of patients before treatment and after 30 days, 90 days, and 180 days of treatment in the two groups were compared. The five-year cumulative survival rate and the incidence of adverse reactions were compared between the two groups. Results. After treatment, the total effective rate of the observation group was 88.03% (103/117), which was higher than that of the control group 69.23% (81/117); the difference was statistically significant ( P < 0.05 ). After treatment, the IPSS score, TCM syndrome score, and VAS score of the two groups were reduced, and those in the observation group were lower than those in the control group; the difference was statistically significant ( P < 0.05 ). After treatment, the quality-of-life scores of the two groups increased, and the observation group was higher than the control group; the difference was statistically significant ( P < 0.05 ). Before treatment, there was no significant difference in serum PSA levels and f-PSA levels when comparing between the two groups of patients ( P > 0.05 ). With the increase of treatment time, the two index levels of the two groups were gradually decreased. After 180 days of treatment, the two index levels of the two groups of patients were significantly lower than those before treatment, and the two index levels of the observation group were significantly lower than those of the control group; the difference was statistically significant ( P < 0.05 ). After treatment, the levels of IgM and IgA in the two groups were decreased, and the level of IgG was increased. The difference between the two groups in the levels of each index before and after treatment was statistically significant ( P < 0.05 ), and the difference between the two groups in the levels of each index after treatment was also statistically significant ( P < 0.05 ). The five-year cumulative survival rate of the observation group was 69.23%, and the five-year cumulative survival rate of the control group was 46.15% ( P < 0.05 ). There was no statistically significant difference between the two groups in the incidence of dizziness, fatigue, and gastrointestinal reactions ( P > 0.05 ), but the difference in the incidence of dysuria as well as dysuria and hematuria was statistically significant ( P < 0.05 ). Conclusion. Jiawei Danggui Beimu Kushen pills are effective in treating prostate cancer, which can effectively reduce the patients’ IPSS score and TCM syndrome scores, relieve the pain, and improve the quality of life of patients. They also have a potential role in regulating serum PSA levels, clearing tumor lesions, reducing postoperative complications, and improving related symptoms.

scholarly journals Metoprolol and atenolol in mild-to-moderate chronic heart failure: The comparison of survival benefit

2005 ◽  
Vol 133 (5-6) ◽  
pp. 242-247 ◽  
Author(s):  
Vera Celic ◽  
Biljana Pencic ◽  
Milica Dekleva ◽  
Sinisa Dimkovic ◽  
Maksimilijan Kocijancic
Keyword(s):  
Heart Failure ◽  
Survival Rate ◽  
Chronic Heart Failure ◽  
Enzyme Inhibitor ◽  
Functional Class ◽  
Cumulative Survival Rate ◽  
Favorable Effect ◽  
Control Group ◽  
End Points ◽  
Cumulative Survival

The clinical end-point of all causes of mortality and cardiovascular hospitalization (combined end-points) is a widely accepted indicator of heart failure survival. The primary aim of this study was to examine the effects of metoprolol and atenool on combined end-points in patients with mild-to-moderate heart failure. This study was designed to be comparative, prospective, and random. The criteria for study inclusion were: age of 70 years or less, New York Heart Association (NYHA) Functional Class II and III, and an ejection fraction of the left ventricle of 40% or less. The patients (a total of 150) on therapy with angiotensin-converting enzyme inhibitor and a diuretic were randomized into three numerically equal therapy groups: 1) an atenolol group; 2) a metoprolol group; and 3) a control group (without beta-blockers). The follow-up period was 12 months. The results were analyzed using: the hisquare test, variance analyses, Kaplan-Meier's model, Wilcox's statistics, and Cox's model. The cumulative survival rate for patients treated with metoprolol was 88%, 78% for patients treated with atenolol, and 48% for patients from the control group. It is clear that the cumulative survival rate for patients treated with metoprolol and atenolol is significantly higher compared to patients from the control group. In addition, the survival rate of patients treated with metoproiol was considerably higher compared to the survival rate of patients treated with atenolol. Metoprolol has significantly reduced the relative risk of combined end-points (71%) compared to atenolol (53%). The results of this comparative study clearly indicate that metoprolol and atenolol have a favorable effect on the survival rate of patients with chronic heart failure. In addition, metoprolol is considerably more effective than atenolol.

scholarly journals A non-bioartificial liver support system combined with transplantation in HBV-related acute-on-chronic liver failure

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Peng Li ◽  
Xi Liang ◽  
Shan Xu ◽  
Ye Xiong ◽  
Jianrong Huang
Keyword(s):  
Survival Rate ◽  
Blood Loss ◽  
Liver Failure ◽  
Control Group ◽  
Observation Group ◽  
Intraoperative Blood Loss ◽  
Chronic Liver Failure ◽  
Short Term ◽  
Liver Support ◽  
Liver Support System

AbstractWe aim to determine the impact of an artificial liver support system (ALSS) treatment before liver transplantation (LT), and identify the prognostic factors and evaluate the predictive values of the current commonly used ACLF prognostic models for short-term prognosis after LT. Data from 166 patients who underwent LT with acute-on-chronic liver failure (ACLF) were retrospectively collected from January 2011 to December 2018 from the First Affiliated Hospital of Zhejiang University School of Medicine. Patients were divided into two groups depending on whether they received ALSS treatment pre-LT. In the observation group, liver function tests and prognostic scores were significantly lower after ALSS treatment, and the waiting time for a donor liver was significantly longer than that of the control group. Both intraoperative blood loss and period of postoperative ICU care were significantly lower; however, there were no significant differences between groups in terms of total postoperative hospital stays. Postoperative 4-week and 12-week survival rates in the observation group were significantly higher than those of the control group. Similar trends were also observed at 48 and 96 weeks, however, without significant difference. Multivariate Cox regression analysis of the risk factors related to prognosis showed that preoperative ALSS treatment, neutrophil–lymphocyte ratio, and intraoperative blood loss were independent predicting factors for 4-week survival rate after transplantation. ALSS treatment combined with LT in patients with HBV-related ACLF improved short-term survival. ALSS treatment pre-LT is an independent protective factor affecting the 4-week survival rate after LT.

scholarly journals Observation of Stereotactic Radiosurgery (Cyberknife) on Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Yang Tang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rate ◽  
Portal Vein ◽  
Stereotactic Radiosurgery ◽  
Cox Proportional Hazards Model ◽  
Cumulative Survival Rate ◽  
Portal Vein Tumor Thrombosis ◽  
Cumulative Survival ◽  
Tumor Thrombosis ◽  
Stable Conditions

The purpose of the study was to analyze the clinical effect of stereotactic radiosurgery (SRS) (Cyberknife) on hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT). Data from 50 patients with HCC-PVTT who received Cyberknife from August 2013 to April 2016 was collected for efficacy analysis. Moreover, survival correlation was evaluated by Cox proportionalhazards model. The total effective rate in 1–3 months after treatment was 64.00%, including 7 cases in complete remission, 12 cases in partial remission, 13 cases in stable conditions, and 18 cases with enlargement; a 4–24-months follow-up (with an average of 11.58 ± 2.58 months) showed that median survival, 1-year cumulative survival rate, and 2-year cumulative survival rate were, respectively, 11.86 ± 1.79 months, 48.00%, and 20.00%. Moreover, the Cox proportional-hazards model indicates that it was with no correlation between lesion diameter, classification of liver function, pre-operative alphafetoprotein, types of hepatitis, number of tumors, ascites, types of tumor emboli, total dose, and survival rate. SRS is effective for HCC-PVTT and serves as an ideal treatment clinically to help preserve patients’ lives, which is worthy of clinical promotion and application.

scholarly journals Geriatric scores can predict long-term survival rate after hip fracture surgery

2019 ◽  
Author(s):  
Carmen da Casa ◽  
Carmen Pablos-Hernández ◽  
Alfonso González-Ramírez ◽  
José Miguel Julián-Enriquez ◽  
Juan F Blanco
Keyword(s):  
Hip Fracture ◽  
Survival Rate ◽  
Barthel Index ◽  
Charlson Index ◽  
Cumulative Survival Rate ◽  
Term Survival ◽  
Cumulative Survival ◽  
Hip Fracture Surgery ◽  
Katz Index ◽  
Fracture Surgery

Abstract Background: The management of hip fractures is nowadays mainly performed in Orthogeriatric Units, one of whose fundamental tools is the application of geriatric scores. The purpose of this study is to establish the potential usefulness of Barthel Index, Katz Index, Lawton-Brody Index and Physical Red Cross Scale geriatric scores as predictors of survival rate and readmission rate in older patients after hip fracture surgery. Methods: We designed a prospective single-center observational study, including 207 older adults over age 65 who underwent hip fracture surgery in the first half of 2014 and followed up to September 2018. Cumulative survival and readmission rates were analyzed by Kaplan-Meier; group comparison, by Log-Rank and hazard ratio, by Cox regression. Results: We found statistical differences (p<0.001) for cumulative survival rate by every geriatric score analyzed (BI HR=0.98 [0.97,0.99]; KI HR=1.24 [1.13-1.37]; LBI HR= 1.25 [1.16, 1.36]; PCRS HR=1.67 [1.37,2.04]). Furthermore, we could determinate an inflection point for survival estimation by Barthel Index (BI 0-55/60-100*, p<0.001, HR=2.37 [1.59,3.53]), Katz Index (KI A-B*/C-G, p<0.001, HR=2.66 [1.80, 3.93], and Lawton-Brody Index (LBI 0-3/4-8*, p<0.001, HR=3.40 [2.09,5.25]). We reveal a correlation of the Charlson Index (p=0.002) and Katz Index (p=0.041) with number of readmissions for the study period. Conclusions: The geriatric scores analyzed are related to the cumulative survival rate after hip fracture surgery for more than 4 years, independently of other clinical and demographic factors. Katz Index in combination with Charlson Index could also be a potential predictor of the number of readmissions after surgery for hip fracture patients.

The All-on-Four Immediate Function Treatment Concept With NobelActive Implants: A Retrospective Study

2011 ◽  
Vol 37 (4) ◽  
pp. 431-445 ◽  
Author(s):  
Charles A Babbush ◽  
Gary T Kutsko ◽  
John Brokloff
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Cumulative Survival Rate ◽  
Treatment Concept ◽  
Single Center ◽  
Cumulative Survival ◽  
Prosthesis Survival ◽  
Immediate Function ◽  
Fixed Prosthesis

Abstract The All-on-Four treatment concept provides patients with an immediately loaded fixed prosthesis supported by 4 implants. This single-center retrospective study evaluated the concept while using the NobelActive implant (Nobel Biocare, Gothenburg, Sweden). Seven hundred eight implants placed in 165 subjects demonstrated a cumulative survival rate of 99.6% (99.3% in maxilla and 100% in the mandible) for up to 29 months of loading. The definitive prosthesis survival rate was 100%.

A New Approach to the All-on-Four Treatment Concept Using Narrow Platform NobelActive Implants

2013 ◽  
Vol 39 (3) ◽  
pp. 314-325 ◽  
Author(s):  
Charles A. Babbush ◽  
Ali Kanawati ◽  
John Brokloff
Keyword(s):  
Survival Rate ◽  
Standard Of Care ◽  
Cumulative Survival Rate ◽  
Implant Design ◽  
Treatment Concept ◽  
New Approach ◽  
Cumulative Survival ◽  
Implant Placement ◽  
Compromised Patients

Although a number of approaches to implant-supported restoration of severely atrophic maxillae and mandibles have been developed, most of these treatments are costly and protracted. An exception is the All-on-Four concept, which uses only 4 implants to support an acrylic, screw-retained provisional prosthesis delivered on the day of implant placement, followed by a definitive prosthesis approximately 4 months later. After the introduction of a new implant design in 2008, a new protocol was developed for provisionally treating patients with severely atrophic jaws using the All-on-Four concept and 3.5-mm-diameter implants. This article describes that protocol and reports on the results of 227 implants after 1 to 3 years of follow-up. The cumulative survival rate was 98.7% at the end of 3 years, with a 100% prosthetic survival rate. Combining the 3.5-mm-diameter NobelActive implants with the All-on-Four concept promises to become a new standard of care for severely compromised patients.

Sign in / Sign up

Export Citation Format

Share Document